KLK10 encodes a secreted serine-type endopeptidase with tumor-suppressor function in multiple cancer types 1. The protein is expressed in choroid plexus epithelium and neuroendocrine organs, where it participates in proteolytic cascades that modulate immune responses 2. In prostate cancer, KLK10 overexpression suppresses cell proliferation, enhances apoptosis, and reduces glucose metabolism through downregulation of anti-apoptotic proteins like BCL-2 and glycolytic enzymes like HK-2 1. Combined KLK10 gene therapy with iodine-131 radiation demonstrates synergistic anti-tumor effects by reducing BCL-2 expression and increasing radiation sensitivity 3. In colorectal cancer, elevated KLK10 expression correlates with advanced tumor stage and liver metastases, serving as an independent prognostic marker for unfavorable disease-free and overall survival 4. Conversely, in pancreatic cancer, KLK10-expressing epithelial cells promote liver metastasis through SPP1-CD44 interactions with fibroblasts 5. KLK10 expression is steroid hormone-regulated through estrogen, androgen, and progestin signaling in breast cancer cells 6. Genetic polymorphisms in KLK10 are significantly associated with stiff-person syndrome susceptibility, suggesting roles in neuroimmune pathology 2. At the transcriptional level, miR-141 negatively regulates KLK10, with implications for hepatocellular carcinoma progression 7. Multiple KLK10 transcript variants exist with potential diagnostic and therapeutic significance 8.